Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24352368 | 0.91 | GNAI3 (0.45) | L3MBTL3L3MBTL1ITGB3ITGA2BKDM1A | |
| SCHEMBL24204316 | 0.88 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1KDM1AGNAI3GNAO1 | |
| SCHEMBL8185716 | 0.85 | PHGDH (0.47) | ITGB3ITGA2BKDM1AGNAI3GNAO1 | |
| SCHEMBL24352085 | 0.84 | HSD11B1 (0.50) | L3MBTL3L3MBTL1KDM1AGNAI3GNAO1 | |
| SCHEMBL26042823 | 0.84 | NPC1 (0.49) | L3MBTL3L3MBTL1KDM1AGNAI3GNAO1 | |
| SCHEMBL24351548 | 0.83 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1KDM1AGNAI3GNAO1 | |
| SCHEMBL24802116 | 0.82 | MEN1 (0.51) | L3MBTL3L3MBTL1ITGB3ITGA2BGNAI3 | |
| SCHEMBL24206835 | 0.81 | GNAI3 (0.44) | ITGB3ITGA2BKDM1AGNAI3GNAO1 | |
| SCHEMBL4000255 | 0.80 | ITGB3 (0.46) | L3MBTL1ITGB3ITGA2BKDM1AALDH1A1 | |
| SCHEMBL8484368 | 0.80 | ALDH1A1 (0.40) | ITGB3ITGA2BKDM1AGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | L3MBTL3 1823/4885L3MBTL1 1119/4885ITGB3 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.